Active pharmaceutical ingredient manufacturers, CDMO players, and intermediates suppliers in India's pharma supply chain.
Sectors represented: Healthcare
Unichem in its journey of several decades, also have the privilege to partner. with renowned pharmaceutical companies in offering third-party manufacturing services a comprehensive range of pharmaceutical. products tailored to the specific requirements of its clients. This association stands as a testament to its reliability, trustworthiness and. commitment to delivering excellence.
Although the CDMO API market is dominated by small. molecules, higher growth is expected in the segments of high-. potency APIs and large molecules. The industry is increasing. backward integration to mitigate the pricing pressure. small. molecules, higher growth is expected in the segments of high-. potency APIs and large molecules. The industry is increasing.
India's drug security should be. ensured by three bulk drug parks in Gujarat, Himachal Pradesh,. and Andhra Pradesh, which also provide a consistent supply of. bulk drug active components. Statutory Reports. 57 g security should be. ensured by three bulk drug parks in Gujarat, Himachal Pradesh,. and Andhra Pradesh, which also provide a consistent supply of. bulk drug active components.
Globally, India is. the third largest producer of API accounting for 8% market share with over 500 different APIs. India contributes 57% of APIs to the prequalified list. of WHO. und 35% of the market. Globally, India is. the third largest producer of API accounting for 8% market share with over 500 different APIs. India contributes 57% of APIs to the prequalified list. of WHO.
Ensuring suppliers have the. financial resources to meet. sustained demand. Manufacturing Capability. Assessing production capacity,. allocated volume and technological. competencies. Regulatory Compliance nsuring suppliers have the. financial resources to meet. sustained demand. Manufacturing Capability. Assessing production capacity,. allocated volume and technological. competencies.
Additionally, the Company seeks. to position itself as a prominent market player both globally by. embracing the most recent technological changes and being. cognizant of ongoing technological advancements to ensure. cost effectiveness. self as a prominent market player both globally by. embracing the most recent technological changes and being.
The following achievements can broadly be summarised for this segment:. 1) 5 new deals have been finalised and agreements signed. 2) 18 new dossiers filed in various countries and 7 new registrations received. 3) 9 new products were launched in the Latam region. 5 new deals have been finalised and agreements signed. 2) 18 new dossiers filed in various countries and 7 new registrations received.
Our Active Pharmaceutical Ingredients. (API) manufacturing facilities benefit. from a vertically integrated business. model that offers better control over. the supply chain, assures the quality. of APIs and achieve cost efficiency. We have several vertically integrated. ANDAs, supported by our in-house API. manufacturing expertise. The 4 in-house API manufacturing ly chain, assures the quality.
By aligning scientific depth with. customer needs, we accelerate the journey from molecule. to market, ensuring speed-to-therapy and long-term value. creation. Our robust capabilities in manufacturing APIs, complex. starting materials, and intermediates help streamline the urney from molecule. to market, ensuring speed-to-therapy and long-term value. creation.
NUTRACEUTICALS. At Divi’s, we take pride in being recognised as one of the world’s largest. API manufacturers, offering a selective list of 30 Generic APIs commercially s. GENERIC APIs. CUSTOM SYNTHESIS. NUTRACEUTICALS. At Divi’s, we take pride in being recognised as one of the world’s largest. API manufacturers, offering a selective list of 30 Generic APIs commercially.
Analytical Development. . Pre-GMP Scale-up. Formulation Development. . Pre-Formulation Studies. . Analytical Development. Ability to manufacture across a. wide range of scale in API as well as. formulations Analytical Development. . Pre-GMP Scale-up. Formulation Development. . Pre-Formulation Studies. . Analytical Development. Ability to manufacture across a. wide range of scale in API as well as.
India. We ensure efficient supply. chain management to deliver. uninterrupted patient care. while optimizing costs. o ensure fulfilment. of objectives and identifying areas. that require further attention. India. We ensure efficient supply. chain management to deliver. uninterrupted patient care. while optimizing costs. Through. consolidated negotiations and the.
We rely on data-driven decision-. making processes, with our KPIs. aligned with our vision and strategy. This approach ensures better. business visibility and refined. decision-making. Mankind Pharma Limited. 5554. Corporate Overview. Annual Report 2023-24 aligned with our vision and strategy. This approach ensures better. business visibility and refined. decision-making. Mankind Pharma Limited.
This allows Indian companies to. offer competitively priced generics,. thus making them attractive for. domestic and international buyers. Initiatives like the Production. Linked Incentive (PLI) scheme. offer financial incentives to boost. domestic production of critical. drugs and Active Pharmaceutical. ingredients (API). ernational buyers. Initiatives like the Production.
Source: Informa – Citeline Clinical Intelligence. 65%. 71%. 79%. 63%. 72%. 59%. 69%. 35%. 29%. 21%. 37%. 28%. 41%. 31%. 2017201820192020202120222023. US FDA New Molecule Approvals Trend. Small MoleculesBiologics. Source: US FDA. 0. 1,000. 2,000. 3,000. 4,000. 5,000. 6,000. 7,000. 8,000. 9,000. 2005. 2006. 2007. 2008. 2009. 2010. 2011. 2012. 2013. 2014. 2015. 2016. 2017. 2018. 2019. 2020. 2021.